Johnson & Johnson announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," ...

Discover trends shaping the pharmaceutical sector. Get insights on rising prescription drug prices, supply chains, and growth ...

Shares with over 50 years of consecutive dividend increases rarely go under the radar. But that might be what’s happening ...

Dividend stocks are one of the most effective long-term strategies. Accordingly, we have chose the top 3 dividend stocks for ...

Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma ...

The portfolio seeks to invest in companies where we believe the valuation and relative rate of return do not reflect the ...

Johnson & Johnson denied wrongdoing after a conservative watchdog group accused the company of violating federal equal ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

South Korea’s biosimilar drug developer Samsung Bioepis has announced that the company has entered into a license, ...

Pfizer's innovative business should grow faster after it divests its off-patent division Upjohn in 2020 to create Viatris and ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.